31
Prof. Gerhard Christofori Prof. Gerhard Christofori Institute of Biochemistry and Genetics Institute of Biochemistry and Genetics Department of Clinical-Biological Sciences Department of Clinical-Biological Sciences University of Basel University of Basel Angiogenesis as a Angiogenesis as a therapeutic target therapeutic target Lecture Lecture Experimentelle Krebsforschung Experimentelle Krebsforschung SS 07 SS 07 Multistage Multistage Tumorigenesis Tumorigenesis

Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

  • Upload
    others

  • View
    6

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

1

Prof. Gerhard ChristoforiProf. Gerhard Christofori

Institute of Biochemistry and GeneticsInstitute of Biochemistry and GeneticsDepartment of Clinical-Biological SciencesDepartment of Clinical-Biological Sciences

University of BaselUniversity of Basel

Angiogenesis as aAngiogenesis as a therapeutic targettherapeutic target

LectureLectureExperimentelle KrebsforschungExperimentelle Krebsforschung

SS 07SS 07

MultistageMultistage Tumorigenesis Tumorigenesis

Page 2: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

2

Multistage Colorectal CarcinogenesisMultistage Colorectal Carcinogenesis

Tumor angiogenesis Tumor angiogenesis

Bergers and Benjamin, 2002, Nat. Rev. Cancer

Page 3: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

3

Increased Increased microvessel microvessel density in tumorsdensity in tumors(for example (for example ductal ductal breast carcinoma)breast carcinoma)

Vasculogenesis/AngiogenesisVasculogenesis/Angiogenesis

Carmeliet, 2003

Page 4: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

4

Tumor angiogenesis in transplanted tumorsTumor angiogenesis in transplanted tumors

Weinberg, 2006

Genetic manipulation of miceGenetic manipulation of mice

Page 5: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

5

The Rip1Tag The Rip1Tag TransgeneTransgene

Hanahan, Nature, 1985

Rip1Tag2 Rip1Tag2 tumorigenesistumorigenesis

Page 6: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

6

Multistage Multistage Tumorigenesis Tumorigenesis in Rip1Tag2 Transgenic Micein Rip1Tag2 Transgenic Mice

““The The angiogenic angiogenic switchswitch””

Page 7: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

7

Cellular Events in Tumor Angiogenesis Cellular Events in Tumor Angiogenesis

Key Key Angiogenic Angiogenic FactorsFactors

Page 8: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

8

Clinical Science www.Clinical Science www.clinsciclinsci.org .org ClinClin. . SciSci. (2005) 109, 227-241. (2005) 109, 227-241

VEGF Family MembersVEGF Family Members

Vascular Endothelial Growth Factors and their Receptors Vascular Endothelial Growth Factors and their Receptors

Cross et al., TIBS, 2003

Page 9: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

9

Hemangioblast

Hematopoietic precursor

VEGFR-2

Alitalo 2001, Stacker 1999

Blood cells

Hematopoiesis

Hematopoietic cells Angioblast

Primary vascular plexus

VEGF-AVEGFR-1VEGFR-2

Vasculogenesis

Enlarged embryonic vasculature(arteries & veins)

VEGF-AVEGFR-1VEGFR-2VEGFR-3

Angiogenesis

EG-VEGFEndothelial

differentiation

„permeable blood vessels“in steroidogenic glands

„tight blood vessels“e.g. brain

Lymphangioblast

VEGF-C VEGF-D VEGFR-3

VEGF-C VEGF-D VEGFR-3

Lymphangiogenesis

prox-1

Lymphatic vessels

VEGFs VEGFs inin Vasculogenesis Vasculogenesis/Angiogenesis/Angiogenesis

Page 10: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

10

Clinical Science www.Clinical Science www.clinsciclinsci.org .org ClinClin. . SciSci. (2005) 109, 227-241. (2005) 109, 227-241

VEGFs VEGFs and theirand their ReceptorsReceptors

Chick CAM AssayChick CAM Assay

Chorio-Allantoic-MembraneChorio-Allantoic-Membrane+/- VEGF-A+/- VEGF-A

VEGF-Knock-outVEGF-Knock-outheterozygous lethal!heterozygous lethal!

Page 11: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

11

Hypoxia-induction of VEGF-A gene expressionHypoxia-induction of VEGF-A gene expression

Harris, 2001

HIF-1HIF-1αα regulation regulation

Harris, 2001

Page 12: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

12

Harris, 2001

Vascular Endothelial Growth FactorsVascular Endothelial Growth Factors

and their Receptorsand their Receptors

Page 13: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

13

TheThe Angiogenic Angiogenic SwitchSwitch

VEGF sequestered by ECM

VEGF released by MMP activity(mast cells,

Vascular Endothelial Growth Factor-AVascular Endothelial Growth Factor-A

Cross et al., TIBS, 2003

Page 14: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

14

Activation ofActivation ofVascular Endothelial Growth Factor-AVascular Endothelial Growth Factor-A

Ferrara et al., 2003

MMPs MMPs in breast (and other) tumorsin breast (and other) tumors

Egeblad and Werb, 2002

Page 15: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

15

Angiogenic Angiogenic Factors and the ECMFactors and the ECM

Sund et al., 2004

A Simplified Picture of Tumor Angiogenesis A Simplified Picture of Tumor Angiogenesis

VEGFs VEGF receptorsFGFs FGF receptorsAngiopoietins Tie-2 (Tie-1?)PDGF B PDGF-β receptorTGFβ TGFβ receptors

Page 16: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

16

AngiopoietinsAngiopoietins

Jones et al., 2001

VEGFs VEGFs and and AngiopoietinsAngiopoietins

Jones et al., 2001

Page 17: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

17

The Fine Balance of Angiogenesis Regulation The Fine Balance of Angiogenesis Regulation

Bergers and Benjamin, 2002, Nat. Rev. Cancer

Angiogenesis InhibitorsAngiogenesis Inhibitors

EndogenousEndogenousTherapeuticTherapeutic

chemicalschemicalsantibodiesantibodiespeptides/proteinspeptides/proteins

Folkman, 2004

Page 18: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

18

Angiogenesis InhibitorsAngiogenesis Inhibitors

Cilengitide

Page 19: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

19

Endogenous angiogenesis inhibitorsEndogenous angiogenesis inhibitors

Experimental Therapy in Rip1Tag2 MiceExperimental Therapy in Rip1Tag2 Mice

Interferon α/βTNP470AngiostatinEndostatinThrombospondinMMP inhibitorsCathepsin inhibitorsGlivec (imatinib

VEFR receptor inhibitors(PTK787,Sugen 6668, …)VEGF-Trap, FGF-TrapVEGF receptor antibodiesImmunoliposomesExendin-4 (GLP1R peptide)AEW471 (IGF1 receptor inhibitor)PDGF receptor inhibitors

Page 20: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

20

Bergers et al. Science 1999

Anti-Anti-Angiogenic Angiogenic Therapy in Rip1Tag2 MiceTherapy in Rip1Tag2 Mice

Weinberg, 2006

Anti-Angiogenic Anti-Angiogenic Therapy in Rip1Tag2 MiceTherapy in Rip1Tag2 Mice

Page 21: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

21

A selection of A selection of anti-angiogenic anti-angiogenic drugs approved drugs approved or or in clinical trialsin clinical trials

Approved for CRCfirst and second line

VEGF-A expression and anti-VEGF-A therapy (VEGF-A expression and anti-VEGF-A therapy (AvastinAvastin))

Borgstrom et al., 1999

Hanrahan et al., 2003

Page 22: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

22

Avastin Avastin in Colorectal Cancerin Colorectal Cancer

Hurwitz et al., 2004

Resistance to Resistance to anti-angiogenic anti-angiogenic therapy?therapy?

Page 23: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

23

Fibroblast Growth Factors and their Receptors Fibroblast Growth Factors and their Receptors

Soluble Receptor ConstructsSoluble Receptor Constructs

Compagni et al., Cancer Res. 2000

Page 24: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

24

VEGFs VEGFs and and FGFs FGFs are required for Tumor Angiogenesis:are required for Tumor Angiogenesis:Rip1Tag2Rip1Tag2 tumorigenesis tumorigenesis in vivoin vivo

Compagni et al., Cancer Res. 2000

A selection of A selection of anti-angiogenic anti-angiogenic drugs approved drugs approved or or in clinical trialsin clinical trials

Page 25: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

25

A selection of A selection of anti-angiogenic anti-angiogenic drugs approved drugs approved or or in clinical trialsin clinical trials

Maturation of Vessels Maturation of Vessels

Pietras and Hanahan, 2005

Page 26: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

26

Two Vascular Systems!Two Vascular Systems!

Jones et al., 2001

The Lymphatic SystemThe Lymphatic System

Page 27: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

27

Lymphatic vesselsLymphatic vessels

Papoutsi et al. Dev. Dyn. 2001

Lymphatic vessel development Lymphatic vessel development

Prox-1 as Prox-1 as master control gene?master control gene?

Oliver and Detmar, 2002

Page 28: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

28

ProxProx-1-induced lymphatic differentiation -1-induced lymphatic differentiation

Petrova et al., 2002

Tumor angiogenesis andTumor angiogenesis and lymphangiogenesis lymphangiogenesis

Vasculogenesis = De novo formation of blood vessels

Angiogenesis = Formation of blood vessels from pre-existing blood vesselsLymphangiogenesis = Formation of lymphatic vessels

Ruoslahti, 2002

Page 29: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

29

Lymphangiogenesis Lymphangiogenesis and angiogenesis in tumors and angiogenesis in tumors

Crnic et al., 2004

VEGF Family Members and their ReceptorsVEGF Family Members and their Receptors

ANGIOGENESIS LYMPHANGIOGENESIS

Page 30: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

30

Rip1VEGF-C

wt

ForcedForced Lymphangiogenesis Lymphangiogenesis in Rip1VEGF-C Mice in Rip1VEGF-C Mice

Mandriota et al., 2001

Rip1Tag2;Rip1VEGF-C

METLN

ForcedForced Lymphangiogenesis Lymphangiogenesis in Rip1Tag2 Mice in Rip1Tag2 Mice

Mandriota et al., 2001

Page 31: Angiogenesis as a therapeutic target · Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis

31

Anti-angiogenic Anti-angiogenic therapytherapy

• ± general mechanism in solid tumors

• no or low resistance

• defined targets

• no angiogenesis in adults, low side effects

• synergism with chemo- and radiotherapy

• anti-metastatic?

• efficacy?

• longterm treatment, side effects?

• resistance afterall?

• lymphangiogenesis - lymph node metastasis

• inflammation!

Reviews:

Carmeliet P. Angiogenesis in health and disease.Nat Med. 2003 Jun;9(6):653-60.

Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease.Cancer Cell. 2002 Apr;1(3):219-27.

Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancermetastasis. Nat Rev Cancer. 2002 Aug;2(8):573-83.

Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch.Nat Rev Cancer. 2003 Jun;3(6):401-10.

Ferrara N, Gerber HP, LeCouter J.The biology of VEGF and its receptors.Nat Med. 2003 Jun;9(6):669-76.

Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002Oct;2(10):795-803.

Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov.2007 Apr;6(4):273-86.